ONMD OneMedNet Corp
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1849380 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY365.1%
TTM net income YoY-412.3%
TTM EPS YoY-14,000.0%
Revenue 3-yr CAGR33.7%
Net income 3-yr CAGR—
Margins
Gross margin-49.7%
Operating margin-440.0%
Net margin-452.9%
FCF margin-285.4%
EBITDA margin-438.6%
Returns
ROE—
ROA-506.7%
ROIC (approx.)—
Asset turnover1.12x
Leverage & solvency
Liabilities / assets277.5%
Debt / equity—
Current ratio0.38x
Interest coverage-289.40x
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-188.2%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.36M | $643,000 |
| Cost of revenue | $1.86M | $924,000 |
| Gross profit | -$503,000 | -$281,000 |
| R&D expense | $1.51M | $1.47M |
| SG&A expense | $6.38M | $7.03M |
| Operating income | -$9.67M | -$9.61M |
| Interest expense | $67,000 | $147,000 |
| Pretax income | -$2.80M | -$10.13M |
| Income tax | $1,000 | $2,000 |
| Net income | -$2.80M | -$10.13M |
| EBITDA | -$9.60M | -$9.55M |
| EPS (basic) | -0.06 | -0.36 |
| EPS (diluted) | -0.06 | -0.36 |
| Weighted avg. shares (diluted) | 44.55M | 28.08M |
| Balance sheet | ||
| Cash & equivalents | $585,000 | $172,000 |
| Receivables | $495,000 | $213,000 |
| Current assets | $2.10M | $3.62M |
| PP&E, net | $56,000 | $108,000 |
| Total assets | $2.15M | $3.73M |
| Current liabilities | $4.83M | $19.23M |
| Short-term debt | $974,000 | $9.38M |
| Long-term debt | $220,000 | $2.32M |
| Total debt | $1.19M | $11.70M |
| Total liabilities | $5.12M | $19.68M |
| Shareholders' equity | -$2.96M | -$15.95M |
| Net debt | $609,000 | $11.53M |
| Shares outstanding | 5.18M | 27.99M |
| Cash flow statement | ||
| Operating cash flow | -$7.50M | -$6.95M |
| Capital expenditure | $13,000 | $51,000 |
| Free cash flow | -$7.52M | -$7.00M |
| Investing cash flow | $2.31M | -$1.98M |
| Financing cash flow | $5.61M | $9.06M |
| Depreciation & amortization | $65,000 | $57,000 |
| Stock-based compensation | $2.03M | $628,000 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.